

 Open access • Posted Content • DOI:10.1101/436246

A role for VPS35 in Brucella intracellular replication revealed by genome-wide siRNA screening — [Source link](#)

Alain Casanova, Shyan Huey Low, Maxime Québatte, Jaroslav Sedzicki ...+5 more authors

Institutions: University of Basel

Published on: 05 Oct 2018 - bioRxiv (Cold Spring Harbor Laboratory)

Topics: Brucella and Actin cytoskeleton

Related papers:

- [A role for the VPS retromer in Brucella intracellular replication revealed by genome-wide siRNA screening](#)
- [A Role for the VPS Retromer in Brucella Intracellular Replication Revealed by Genomewide siRNA Screening](#)
- [Toxoplasma gondii subverts the host ESCRT machinery for parasite uptake of host cytosolic proteins](#)
- [How Viruses Use the Endoplasmic Reticulum for Entry, Replication, and Assembly](#)
- [The Effector Cig57 Hijacks FCHO-Mediated Vesicular Trafficking to Facilitate Intracellular Replication of Coxiella burnetii](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/a-role-for-vps35-in-brucella-intracellular-replication-6q32t1f9vm>

1 **A role for the VPS retromer in *Brucella* intracellular replication revealed**
2 **by genome-wide siRNA screening**

3 Alain Casanova^{a,b}, Shyan Huey Low^{a,c}, Maxime Québatte^a, Jaroslaw Sedzicki^a, Therese
4 Tschon^a, Maren Ketterer^a, Kevin Smith^{a,d}, Mario Emmenlauer^{a,e}, Houchaima Ben-Tekaya^{a,f},
5 and Christoph Dehio^{a,#}

6
7 ^aBiozentrum, University of Basel, Switzerland

8
9 Running Head: The VPS-Retromer is required for *Brucella* trafficking

10

11

12 #Address correspondence to Christoph Dehio, christoph.dehio@unibas.ch

13 ^bPresent address: Novartis Pharma Schweiz AG, Rotkreuz, Switzerland

14 ^cPresent address: Lee Kong Chian School of Medicine, Nanyang Technological University

15 ^dPresent address: Science for Life Laboratory, KTH Royal Institute of Technology, School of
16 Computer Science and Communication, Solna, Sweden

17 ^ePresent address: BioDataAnalysis GmbH, Munich, Germany

18 ^fPresent address: University Hospital Basel, Basel, Switzerland

19

20 AC, SL, and MQ. contributed equally to this work

21

22 Word count for the abstract: 238

23 Word count for the text: 7563

24

25 Key words: *Brucella*, siRNA, VPS retromer, VPS35, VPS26, RAB7A, replicative niche

26 **Abstract**

27 *Brucella*, the causing agent of brucellosis, is a major zoonotic pathogen with worldwide
28 distribution. *Brucella* resides and replicates inside infected host cells in membrane-bound
29 compartments called BCVs (*Brucella*-containing vacuoles). Following uptake, *Brucella*
30 resides in eBCVs (endosomal BCVs) that gradually mature from early to late endosomal
31 features. Through a poorly understood process that is key to the intracellular lifestyle of
32 *Brucella*, the eBCV escapes fusion with lysosomes by transitioning to the rBCV (replicative
33 BCV), a replicative niche directly connected to the endoplasmic reticulum (ER). Despite the
34 notion that this complex intracellular lifestyle must depend on a multitude of host factors, a
35 holistic view on which of these components control *Brucella* cell entry, trafficking and
36 replication is still missing. Here we used a systematic cell-based siRNA knockdown screen in
37 HeLa cells infected with *Brucella abortus* and identified 425 components of the human
38 infectome for *Brucella* infection. These include multiple components of pathways involved in
39 central processes such as cell cycle, actin cytoskeleton dynamics or vesicular trafficking. Using
40 assays for pathogen entry, knockdown complementation and co-localization at single-cell
41 resolution, we identified the requirement of the VPS retromer for *Brucella* to escape the
42 lysosomal degradative pathway and to establish its intracellular replicative niche. We thus
43 validated a component of the VPS retromer as novel host factor critical for *Brucella*
44 intracellular trafficking. Further, our genome-wide data shed light on the interplay between
45 central host processes and the biogenesis of the *Brucella* replicative niche.

46

47 **Importance**

48 With >300,000 new cases of human brucellosis annually, *Brucella* is regarded as one of the
49 most important zoonotic bacterial pathogen worldwide. The causing agent of brucellosis
50 resides inside host cells within vacuoles termed *Brucella* containing vacuoles (BCVs).
51 Although few host components required to escape the degradative lysosomal pathway and to
52 establish the ER-derived replicative BCV (rBCV) have already been identified, the global
53 understanding of this highly coordinated process is still partial and many factors remain
54 unknown. To gain a deeper insight into these fundamental questions we performed a genome-
55 wide RNA interference (RNAi) screen aiming at discovering novel host factors involved in the
56 *Brucella* intracellular cycle. We identified 425 host proteins that contribute to *Brucella* cellular
57 entry, intracellular trafficking, and replication. Together, this study sheds light on previously
58 unknown host pathways required for the *Brucella* infection cycle and highlights the VPS
59 retromer components as critical factors for the establishment of the *Brucella* intracellular
60 replicative niche.

61

62 **Introduction**

63 Cellular invasion is a common strategy shared by many bacterial pathogens of human and
64 animals in order to escape host defenses and to establish a protected replicative niche. This
65 notably applies to the human pathogens of the genus *Salmonella*, *Shigella*, *Legionella*, or
66 *Brucella* (1-3). Knowledge of the host cellular pathways that are subverted by these pathogenic
67 bacteria in order to reach and/or establish their intracellular replicative niches can be highly
68 instructive for the development of new treatment strategies. *Brucella* is a facultative
69 intracellular zoonotic pathogen causing animal and human brucellosis. With more than 300,000
70 new cases of human brucellosis every year, *Brucella* is regarded as one of the most important
71 zoonotic bacterial pathogen worldwide (4-6). There is currently no effective vaccination for
72 humans and even prolonged combinatory antibiotic treatments do not fully protect against
73 relapses (7). Therefore, *Brucella* remains a significant threat to public health and to the
74 economy in endemic areas, and thus new treatment strategies to circumvent *Brucella* infections
75 are highly needed.

76 At the cellular level, *Brucella* invades both phagocytic and non-phagocytic cells where bacteria
77 persist and replicate inside membrane-bound compartments – the *Brucella* containing vacuoles
78 (BCVs). BCVs sequentially interact with components of the host early and late endocytic
79 pathway (eBCVs) then transit to establish the replicative niche (rBCVs) in vesicles that are
80 directly connected to the endoplasmic reticulum (ER) (8) and harbor ER-specific markers, such
81 as SEC61 and calnexin (8-10). Several critical steps for the intracellular journey of *Brucella*
82 and their associated host factors have been resolved. For instance, adherence to the host cell
83 surface is mediated via interaction with sialic acid residues or binding to fibronectin and
84 vitronectin (11, 12). Internalization requires actin remodeling via the activity of the small
85 GTPases RAC, RHO and direct activation of CDC42 (13). Upon internalization, bacteria are
86 contained within eBCVs that successively associate with a subset of endosomal markers,

87 starting with RAB5, the early endosomal antigen (EEA1), the transferrin receptor (TfR), as
88 well as the lipid rafts component flotillin-1 (9, 14-16). Next, the eBCVs associate with the late
89 endosomal markers RAB7, RILP (RAB7's effector RAB interacting lysosomal protein),
90 LAMP-1 (Lysosomal-associated membrane protein 1), and transiently with autophagosomal
91 markers (9, 10). As they evolve late endosomal characteristics, acidification of the eBCVs
92 serves as a trigger for the expression of the VirB type IV secretion system (T4SS, (17, 18)).
93 This major pathogenicity factor is required to prevent the complete fusion of eBCVs with
94 lysosomes, consequently allowing a fraction of the internalized *Brucella* to avoid host-
95 mediated degradation, and promotes the maturation of the eBCVs towards the rBCVs (16, 18).
96 Noteworthy, the T4SS effectors responsible for this escape remain largely elusive, despite a
97 growing repertoire of identified candidates (recently reviewed in (19)). Most recently, it was
98 discovered that subversion of both anterograde and retrograde transport and recruitment of
99 Conserved Oligomeric Golgi (COG) tethering complex-dependent vesicles to the BCV
100 promotes the establishment of the *Brucella* replicative niche (20). Importantly, despite all these
101 findings, the precise mechanism(s) resulting in diversion of eBCVs from the endolysosomal
102 pathway towards the ER-associated replicative compartment (rBCVs) is still largely
103 unresolved. The same holds true for host factors required for maintenance of the replicative
104 niche.

105 In this study, we took a systems-level approach to gain a deeper insight into these fundamental
106 questions. Using a genome-wide RNA interference (RNAi) screening approach, we identified
107 425 host proteins whose knockdown either increases (202) or decreases (223) *Brucella*
108 intracellular replication. Beside the rediscovery of several previously identified host targets,
109 that validates our approach, data reveals numerous novel candidate components that can
110 modulate *Brucella* cellular entry, trafficking, and/or replication. Among these targets, we
111 identified VPS35 and VPS26A, two components of the trimeric vacuolar protein sorting (VPS)

112 complex (termed here VPS retromer), which are required for the diversion of BCVs from the
113 endolysosomal pathway and the establishment of the intracellular replicative niche.

114

115 **Results**

116 **A genome-wide siRNA screen reveals novel host pathways involved in *Brucella* infection**

117 To identify novel host factors important for *Brucella* intracellular infection, we performed a
118 genome-wide siRNA perturbation screen on the human epithelial cell line HeLa (ATCC®
119 CCL-2) combined with bacterial infection at biosafety-level 3. Infections of the siRNA-treated
120 cells were performed with a GFP expressing strain of *B. abortus* and the outcome was analyzed
121 at 48 h post-infection (hpi) using automated fluorescence microscopy (21, 22). Infection
122 scoring was determined with a tailored high-content analysis workflow (Fig. 1 and Materials
123 and Methods). In brief, a model of *Brucella* replication was fitted to the pathogen intensity
124 distribution to gain an infection classification independent of absolute fluorescence intensity.
125 Further, we implemented an image intensity normalization coupled with a novel pathogen-to-
126 cell association approach, which enabled quantitative measurement of the pathogen intensity
127 distribution (Materials and Methods). An overview of the results is presented in Fig. S1. To
128 account for the well-known confounding off-target effects associated with siRNA technology
129 (recently reviewed in (23)), we applied a multiple orthologous RNAi reagents approach
130 (MORR (24)) with $n \geq 5$ perturbations per host gene. Further, we applied the Redundant siRNA
131 Analysis (RSA) algorithm (25) on the entire screening data to reduce the number of false
132 positives caused by off-target effects of single siRNAs and to favors genes with a reproducible
133 phenotype confirmed by independent siRNAs. Genes matching a Benjamini-corrected RSA p-
134 value ≤ 0.01 with more than 3 hit wells were considered as significant and selected for further
135 analysis (see also Material and Methods). As a result, we identified 425 significant hits
136 affecting *Brucella* infection. These comprised 223 down-hits (Fig. S1A, red and Table S1) and

137 202 up-hits (Fig. S1A, green and Table S2). Single siRNA data points are presented in Fig. S2
138 (down-hits) and Fig. S3 (up-hits). A panel of representative images from the screen is presented
139 in Fig. 2A. Hit genes were further stratified by gene-annotation enrichment analysis and
140 functional annotation clustering using DAVID (26), protein-protein interaction network using
141 the STRING database (27), as well as manual datamining. The functional categories enriched
142 in our hit lists are presented in Fig. 2B-D together with the high confidence protein-protein
143 interaction network for targets that reduced (Fig. 2E) or increased (Fig. 2F) *Brucella* infection
144 upon knockdown. Gene ontology and functional clustering analysis indicated a rather small
145 overlap in enriched pathways when considering up or down hits (Fig. 2B-D). The most
146 prominent clusters that positively affected infection upon knockdown comprised components
147 involved in the control or the modulation of central cellular processes such as protein synthesis,
148 transcription and mRNA processing, and cell cycle progression, as well as clathrin-mediated
149 endocytosis (Fig. 2 and Table S2). The most prominent clusters that negatively affected
150 infection upon knockdown comprised signaling pathways involved in actin-remodeling and
151 phagocytosis. These included most core components of the Actin-related protein-2/3 complex
152 (ARP2/3: ARPC2, ARPC3, ACTR2 and ACTR3), and one of its main modulator, the WASP
153 regulatory complex (WRC: CYFIP1, WASF3, NCKAP1, and ABI3). Down-hits also
154 comprised multiple components involved in TGF- β and Eph signaling as well as further
155 vesicular/endocytic pathways (Fig. 2 and Table S1). Among all these factors we can highlight
156 the Ras related protein RAB7A, which is needed for *Brucella* trafficking to the replicative
157 niche (10), the small GTPases RAC1 and CDC42, which are involved in *Brucella*
158 internalization into non-phagocytic cells (13) as well as the transmembrane glycoprotein
159 SLC3A2 (CD98hc), involved in both bacterial uptake and intracellular multiplication (28).
160 Since the role of these individual components has already been described in the context of

161 *Brucella* infection, they can be considered as benchmark to our results, and globally validate
162 our systems-level perspective of the human infectome for *Brucella* infection.

163

164 **Pathogen entry assay identifies a role for VPS35, VPS26A and SEC61 γ in *Brucella* post-**
165 **entry trafficking**

166 To further dissect the role of the identified genes in the progression of *Brucella* infection, we
167 took advantage of a pathogen entry assay previously developed in our laboratory (29). Briefly,
168 at 4 hpi host cell membrane-impermeable gentamicin was added to selectively kill extracellular
169 *Brucella* and concomitantly cell membrane-permeable anhydrotetracyclin was added to induce
170 expression of a plasmid-encoded reporter in the viable intracellular bacteria. At 8 hpi this
171 approach allowed us to robustly identify individual intracellular bacteria and to quantify the
172 bacterial load before intracellular replication is initiated (Fig. 3A and Material and Methods).
173 For this assay, we selected a number of genes from the different pathways identified in the
174 genome-wide screen as well as additional genes supplementing them (Table S3). The results
175 of this entry assay were plotted against a matching endpoint assay (intracellular replication at
176 48 hpi). Strikingly, most of the tested genes displayed a direct correlation between the results
177 of the entry and the endpoint assay ($r^2=0.763$). This was the case for components involved in
178 the actin-remodeling pathway (RAC1, ACTR3, CYFIP1) or those involved in the TGF β
179 signaling (SMAD4, TGFBR1, TGFBR2), which strongly reduced both entry and subsequent
180 intracellular replication (Fig. 3B and Table S3). Similarly, the components of the clathrin
181 pathway GAK and AP2S1 both increased bacterial entry and replication (Fig. 3B and
182 Tables S3-4). This support their involvement in *Brucella* entry into non-phagocytic cells,
183 without excluding an additional role at any further stage of the infection. To identify
184 components with a divergent outcome between entry and replication, we selected genes
185 diverging by more than one standard deviation to the fitted data. Six genes matched this

186 criterion (Fig. 3B). Three genes displayed an apparent higher effect on pathogen entry than
187 subsequent replication (albeit at a rather modest level). These were the small GTPases CDC42
188 (13), the $\alpha 1$ subunit of the Na⁺,K⁺-ATPase ATP1A1(30) and the subtilisin-like
189 endoproteinases FURIN (31). Most strikingly, three genes displayed a stronger reduction in
190 endpoint replication compared to entry. Knockdown of Sec61 γ - a central element of the ER-
191 protein translocation machinery (see for instance (34), which has been previously involved
192 in *Brucella* infection (35), showed a strong decrease in intracellular replication albeit no effect
193 on pathogen entry. Similarly, our assay identified the vacuolar protein sorting associated
194 proteins VPS35 and VPS26A - two essential components of the VPS retromer complex
195 (recently reviewed in (32, 33)). These genes and associated pathway(s) thus likely represent
196 novel components controlling the post-entry trafficking of *Brucella* towards its replicative
197 niche and/or are themselves required for the establishment or maintenance of the rBCVs.
198 For the present study, we further focused on the role of VPS35 and the VPS retromer in
199 *Brucella* trafficking as it was the most prominent hit in our entry assay.

200

201 **The VPS retromer is important for *Brucella* intracellular replication**

202 The retromer complex orchestrates the recycling of numerous transmembrane proteins from
203 early and maturing endosomes either to the trans-Golgi network (TGN) or back to the plasma
204 membrane. Formed by a heterotrimeric complex consisting of VPS26, VPS29, and VPS35, the
205 VPS retromer is conserved from yeast to human. However, the individual retromer sub-
206 complexes have functionally diverged to organize multiple distinct sorting pathways,
207 depending on the association with different accessory factors (32, 33). To further decipher the
208 role of the retromer in *Brucella* trafficking and intracellular replication we specifically browsed
209 our genome-wide siRNA data for retromer-associated proteins (Fig. 4A and D). Further to
210 VPS35 and VPS26A, already identified both in the genome wide and in the entry screen

211 (Fig. 2E and Fig. 3B), knockdown of VPS26B (the paralogue of VPS26A) resulted in a
212 significant reduction in *Brucella* infection (Fig. 4D). Depletion of VPS29, the third core
213 component of the VPS retromer, resulted only in a mild reduction of *Brucella* infection and did
214 not reach significance due to the wide spread of data obtained for the cohort of 9 individual
215 siRNAs tested (suggestive of strong off-target effects). Next to the retromer component,
216 knockdown of the small GTPase RAB7A showed the strongest reduction in intracellular
217 *Brucella* (Fig 4D). However, neither SNX3, that together with the VPS retromer forms the
218 SNX3 retromer nor SNX27, another retromer-associated component involved in endosome-to-
219 plasma membrane trafficking (36, 37), displayed significant effect (Fig. 4D). Depletion of
220 SNX1 and SNX5, two of the four sorting nexins of the SNX-BAR retromer (38), even seems
221 to enhance *Brucella* infection (although they did not pass our hit-selection criterion) while the
222 two others, SNX2 and SNX6, showed no effect (Fig. 4D). Noteworthy, the functional
223 association of the SNX-BAR sorting nexins with the VPS retromer has been challenged by two
224 recent publications, which rather support a VPS-independent action of SNX-BAR (39, 40).
225 Collectively, our data indicate that the observed post-entry impairment in *Brucella* intracellular
226 replication is specifically linked to the integrity of the heterotrimeric VPS retromer, although
227 involvement of further components in this process cannot be excluded.

228 To validate the requirement of VPS35 on *Brucella* infection and to rule out any off-target
229 effects, we performed a complementation experiment using a VPS35 cDNA insensitive to a
230 co-expressed shRNA (41). While shRNA knockdown of endogenous VPS35 inhibited *Brucella*
231 infection, as detected in our genome-wide approach, ectopic expression of the shRNA-
232 insensitive cDNA of VPS35 rescued the phenotype (Fig. 4B and C), confirming that depletion
233 of VPS35 indeed negatively affects *Brucella* infection. We further confirmed the observed
234 requirement of the VPS retromer for *Brucella* intracellular replication by determining
235 intracellular bacterial load at different infection time of siRNA-transfected cells using colony

236 forming unit (CFU) determination (Material and Methods). At 6 hpi, no significant difference
237 to the control was detected, with the exception of a small increase in intracellular bacteria upon
238 VPS35 knockdown (Fig. 4E). Importantly, at 20 h and 44 hpi, siRNA knockdown of either
239 VPS35, VPS29, or VPS26 resulted in a significant decrease of viable intracellular *Brucella*
240 compared to control-treated cells (Fig. 4E) confirming the data obtained by our microscopy-
241 based entry screen (Fig. 3). Further, efficiency of siRNA knockdown was confirmed by
242 Western blot analysis (Fig. 4F and Table S4). Together, these results corroborate the
243 importance of each constituent of the VPS retromer, including VPS29, for *Brucella* to reach
244 and possibly to maintain its intracellular replicative niche.

245

246 **VPS35 knockdown prevents *Brucella* escape from the lysosomal pathway**

247 Transient association with the lysosomal marker LAMP-1 is a hallmark of BCV trafficking
248 during the first hours of infection. This association is eventually lost for those bacteria that
249 manage to escape the host degradative pathway. Thus, to investigate the role of VPS35 in
250 *Brucella* trafficking and to assess at which stage it could be required for the establishment of
251 the intracellular replicative niche, we quantified *Brucella* co-localization with LAMP-1 in
252 siRNA-treated and control cells. To this end, we analyzed *Brucella*-infected HeLa cells at 6
253 and 18 hpi and determined the percentage of LAMP-1 co-localization for each detected
254 bacteria, combining immunostaining and confocal microscopy (Fig. 5 and Materials and
255 Methods). At 6 hpi, most *Brucella* were found within LAMP-1-positive vesicles in both control
256 and siRNA-treated cells (Fig. 5A-D, F), indicating that VPS35 function is not required for the
257 early trafficking of the BCVs. However, loss of LAMP-1 association at 18 hpi was mainly
258 detected in control cells whereas most *Brucella* remained in a LAMP-1 positive compartment
259 upon VPS35 knockdown (Fig 5B, C). Accordingly, VPS35 depletion strongly reduced
260 intracellular replication of *Brucella* 18 hpi (Fig. 5G) compared to control cells (Fig. 5E).

261 Altogether, our single cell co-localization analysis demonstrates the requirement of VPS35,
262 and thus of a functional VPS retromer, for the diversion of BCVs from the lysosomal pathway
263 and for the subsequent establishment of a successful replicative niche.

264

265 **Discussion**

266 The different membrane-bound organelles that compose the secretory pathway and the endo-
267 lysosomal system of eukaryotic cells constitute targets of choice for many intracellular
268 pathogens, which have evolved highly diverse strategies to hijack and/or subvert these
269 trafficking pathways to their benefit (2, 3). In that context, the importance of retrograde
270 trafficking for the infection cycle of a number of human pathogens (viruses and bacteria) has
271 been recognized in the past years (e.g., (42, 43)). This is for instance the case for *Chlamydia*
272 *trachomatis*, which uses its effector LncE to subvert host restriction via direct interaction with
273 SNX5, thereby disrupting retromer trafficking (44, 45). Further pathogens have been shown to
274 specifically target the VPS retromer, using or subverting its function to their advantage. For
275 instance, the Hepatitis C virus interacts with VPS35 through its protein NS5A. This viral
276 protein is recognized as VPS retromer cargo and its interaction with VPS35 supports viral
277 replication (46). Among bacterial pathogens, the best-studied example to date is the subversion
278 of the VPS retromer function by the T4SS effector RidL of *Legionella pneumophila*. RidL was
279 shown to interact with VPS29, inhibiting retromer activity by outcompeting the binding of the
280 VPS retromer regulator TBC1d5 and thereby promoting *Legionella* intracellular replication
281 (47-49). Most recently, integrity of the *Salmonella* containing vacuole was shown to be
282 maintained by the direct interaction of the SPI-2 T3SS effector SseC with the VPS retromer
283 (50). In this study, we report the involvement of the VPS retromer in *Brucella* intracellular
284 cycle. More specifically, we show that the VPS retromer integrity is required for *Brucella* to
285 escape the host degradative pathway, as supported by the inability of the eBCVs to mature

286 upon VPS35 knockdown towards LAMP-1 negative rBCVs. We further show that this VPS-
287 retromer-dependent process takes place after internalization and early trafficking, between 6 h
288 and 18 hpi, matching the estimated timing of the eBCV-to-rBCV transition. It is thus tempting
289 to speculate that the VPS retromer, possibly together with RAB7A, plays a role in this yet
290 elusive but essential branching point of *Brucella* intracellular trafficking i.e. diversion from the
291 lysosomal pathway towards its ER-associated replicative niche. An alternative, yet non-
292 exclusive hypothesis is that the VPS retromer is involved in the establishment of the rBCV,
293 possibly by providing host factors and/or membranes that follow retrograde trafficking. A
294 further role for the VPS retromer in the maintenance of the rBCV cannot be excluded based on
295 our results. With the accumulation of functional data and the increasing number of described
296 interactors, the VPS retromer is nowadays largely appreciated as recruiting hub that
297 orchestrates the retrograde endosomal trafficking of numerous cargos to the TGN or the plasma
298 membrane (32, 33, 51). This versatility however obscures the identification of the underlying
299 mechanism(s) by which VPS35 and the VPS retromer may contribute to *Brucella* intracellular
300 fate. Further browsing our dataset for the effect of known VPS retromer interactors failed
301 resolving the VPS retromer-dependent pathway(s) – if any – that is required for *Brucella*
302 intracellular replication. The only VPS retromer interactor that we unambiguously identified is
303 the small GTPase RAB7A, which is essential for the recruitment of the retromer to endosomal
304 membranes (52, 53). Importantly, association of this upstream interactor to the eBCV is a well-
305 established hallmark of early *Brucella* intracellular trafficking (9, 10, 16). Moreover, over-
306 expression of a RAB7 dominant negative allele (RAB7^{T22N}) impairs the establishment of the
307 *Brucella* replicative niche (10). This finding was recapitulated by our siRNA knockdown
308 approach, strengthening the role of RAB7 in controlling BCVs' fate, albeit by an unknown
309 mechanism. Considering that the recruitment of the retromer to endosomal membranes is
310 strictly dependent on the presence of RAB7, it is conceivable to assume that depletion of RAB7

311 prevents the recruitment of VPS35 to the BCV, consequently explaining the RAB7-
312 dependency observed for *Brucella* replication. Alternatively, very recent findings have
313 established that retromer depletion in Hela cells actually results in the hyper-activation of
314 RAB7, which causes an overall depletion of the RAB7 pool on endo-membranes (54). That
315 drastic consequence could also imply an indirect effect of the observed retromer requirement
316 for *Brucella* trafficking, by acting at the level of RAB7 activity and its availability for the BCV
317 maturation. However, our results indicate that the effect of RAB7A or VPS35 siRNA
318 knockdown are not entirely congruent. Whereas depletion of either factor impairs *Brucella*
319 intracellular replication, only RAB7A knockdown showed a marked effect on pathogen entry
320 whereas VPS35 appears to be only required at a later stage of the infection. The implications
321 of the newly described feedback signaling on RAB7 triggered by the retromer depletion, as
322 well as the relative contribution of the VPS retromer and RAB7 for the transition of the eBCVs
323 to rBCVs should be addressed in future studies.

324 Besides the retromer complex, our study pinpointed the involvement of several host pathways
325 in *Brucella* infection, which had not yet been associated with this process. The most prominent
326 cluster negatively affecting infection upon knockdown comprises factors involved in actin
327 remodeling and actin dynamics as well as associated signaling pathways. Apart from an early
328 association of Arp2/3 with BCVs (55), surprisingly little is known about the exact role played
329 by the Arp2/3 complex or the WASP regulatory complex and their regulators during and
330 possibly after *Brucella* internalization. Here as well, further studies will be needed to decipher
331 the precise nature of their involvement. Finally, we also found that members of the TGF- β and
332 FGF signaling pathways promote *Brucella* infection as their depletion resulted in decreased
333 *Brucella* infection. Interestingly, it has previously been reported that patients with brucellosis
334 show higher TGF- β 1 serum levels, a finding that is correlated with depressed T cell function
335 (56). Further, B cells were also shown to produce TGF- β at early stages of infection with

336 *Brucella* in mice (57). A possible immunosuppressive role for this pathway during *Brucella*
337 infection should be further investigated.

338 Summing-up, we believe that the genes and pathways identified in this study constitute a rich
339 resource towards the understanding of *Brucella* intracellular trafficking, which ultimately
340 should allow development of new approaches to controlling *Brucella* infections in human.

341

342 **Material & Methods**

343 **Cell lines and plasmid constructs**

344 All experiments were performed in the human cervical carcinoma epithelial cell line (Hela)
345 ATCC® CCL-2. Infections were performed using *Brucella abortus* 2308 carrying the
346 constitutive GFP expression plasmid pJC43 (*aphT::GFP* (58)), pAC042.08 for entry assay
347 (*aphT::dsRed,tetO::tetR-GFP* (29)) or pAC037 (*aphT::cerulean*, this study) for rescue
348 experiments. Cells and bacteria were grown as described in (22, 29). pAC037 was constructed
349 by replacing dsRed from pJC44 (10) with Cerulean from pCERC-1 (59). Cerulean was
350 amplified using prAC082 (TGGATCCGAAAGGAGGTTTATTAAATGGTGAGCAAGGG-
351 CGAGGAGC) and prAC083 (TCTAGAGCTAGCTTACTTGTACAGCTCGTC) and cloned
352 into pJC44 by restriction/ligation using BamHI and XbaI. The ribosomal binding site which
353 was lost on pJC44 using the above restriction was re-introduced on prAC082.

354 **siRNA reverse transfection**

355 Reverse siRNA transfection was performed as described in (22, 29) with minor adjustments.
356 In brief, Genome-wide screens were performed with Dharmacon ON-TARGETplus SMART
357 pool (pool of 4 siRNA per gene) and Qiagen Human Whole Genome siRNA Set HP
358 GenomeWide (QU, 4 individual siRNAs for each target). Further validation screens included
359 Ambion Silencer and Ambion Silencer Select custom libraries (with up to 6 additional siRNAs
360 for about 1000 genes) and Sigma MISSION esiRNA libraries for 1900 genes. All screening

361 experiments were conducted in a 384-well plate format. Each plate contained negative controls
362 such as mock (transfection reagent only) and scrambled (non-targeting) siRNA. In addition,
363 general siRNA controls for transfection efficiency and toxicity (e.g. Kif11, Fig. S1C) as well
364 as positive controls (e.g. Cdc42, Rac1) that are known to have an effect on *Brucella* infection
365 (13) were added to each plate. Based on Kif11, the average transfection efficiency reached
366 97.6% (91.5 – 99.99). The following specifications apply to all siRNA screens except the QU
367 siRNA library where specifications are given in brackets. RNAiMAX in DMEM without fetal
368 calf serum (FCS) was added to each well containing 1.6 pmol siRNA (QU: 1 pmol) or 15 ng
369 esiRNA. Screening plates were then incubated at room temperature (RT) for 1 h. Following
370 incubation, 500 HeLa cells were seeded per well in DMEM (FCS 10% final). Plates were
371 incubated at 37°C and 5% CO₂ for 72 h prior to infection. For assays in 96- and 24-well formats
372 reverse transfections were performed in 6-well plates and subsequently reseeded in the
373 respective plate format. On-target or control siRNAs were added to reach a final siRNA
374 concentration of 20 nM together with RNAiMAX transfection reagent in DMEM without FCS.
375 After 30 min of complex formation at room temperature, 110,000 HeLa cells in DMEM/10%
376 FCS were added to each well. After 48 h transfection, cells were harvested by trypsinization
377 and reseeded in DMEM/10%FCS (96-well plates: 2'800 cells per well; 24-well plates: 50,000
378 cells per well). The next day cells were infected as described hereafter. The following siRNAs
379 used for CFU determination, colocalization experiments, and/or immunoblotting validation
380 were purchased from Qiagen (Hilden/Germany): VPS35 (SI00760690); VPS26A
381 (SI00760543); VPS26B (SI00631267); VPS29 (SI00760613); all star negative (0001027281);
382 all star death kif11 (0001027299).

383 **Infection**

384 For the genome-wide and confirmation screens, infections were performed in 384-well plates
385 as described in (22, 29). In short, *B. abortus* 2308 pJC43 (*aphT::GFP* (58)) was grown in TSB

386 medium containing 50 µg/ml kanamycin at 37°C to an OD of 0.8 - 1.1. Bacteria were then
387 diluted in DMEM/10% FCS and added at a final MOI of 10,000. Plates were centrifuged at
388 400 x g for 20 min at 4°C to synchronize bacterial entry. After 4 h incubation at 37°C and 5%
389 CO₂, extracellular bacteria were killed by exchanging the infection medium by DMEM/10%
390 FCS supplemented with 100 µg/ml gentamicin. After a total infection time of 44 h, cells were
391 fixed with 3.7% PFA for 20 min at RT. For the entry assay, infections were performed as
392 described in (29). In brief, transfected cells were infected with *B. abortus* 2308 pAC042.08 for
393 4 h after which GFP expression was induced for 4 h by the addition of Anhydrotetracycline
394 (100 ng/ml) during the gentamicin killing of extracellular bacteria. Follow-up experiments and
395 colocalization assays were performed according to the above-described protocol in 96-well and
396 24-well plates, respectively. For the colocalization assay cells were infected at a MOI of 2,000.
397 2 hpi cells were washed three times with DMEM/10% FCS containing gentamicin (100 µg/ml).
398 After the indicated incubation time cells were washed three times with PBS and finally fixed
399 for 20 min in 3.7% PFA (in PBS).

400 **Imaging with high-throughput microscopy**

401 Microscopy was performed with Molecular Devices ImageXpress microscopes. MetaXpress
402 plate acquisition wizard with no gain, 12 bit dynamic range, 9 sites per well in a 3x3 grid was
403 used with no spacing and no overlap and laser-based focusing. DAPI channel was used for
404 imaging nucleus, GFP for bacteria, and RFP for F-actin or dsRed of bacteria in the entry assay.
405 Robotic plate handling was used to load and unload plates (Thermo Scientific). The objective
406 was a 10X S Fluor with 0.45NA. The Site Autofocus was set to “All Sites” and the initial well
407 for finding the sample was set to “First well acquired”. Z-Offset for Focus was selected
408 manually and manual correction of the exposure time was applied to ensure a wide dynamic
409 range with low overexposure. Images from the different siRNA screens are available upon
410 request.

411 **Image analysis**

412 Images were analyzed with the screeningBee analysis framework from BioDataAnalysis
413 GmbH. To correct for uneven illumination inherent in wide-field microscopic imaging, an
414 illumination correction model was computed for every plate using Cidre (60). To ensure that
415 the Cidre-corrected image intensities fall within the range [0.0, 1.0] a linear transformation for
416 pixel intensities was computed that maps the 0.001-quantile to 0.01 and the 0.999-quantile to
417 0.99 post-illumination correction. Illumination correction and intensity scaling were performed
418 as pre-processing steps for every image prior to analysis.

419 To reduce the signal of *Brucella* DNA in the DAPI channel, a linear transform of the GFP
420 channel was subtracted from the DAPI channel, with the linear transformation parameters f , o
421 estimated in the following way: a mapping of GFP pixels to DAPI pixels was constructed so
422 that for all intensities in the GFP images, the list of corresponding intensities in the DAPI
423 images were recorded. For every list of DAPI intensities, only the mean intensities were
424 retained. This creates a mapping of GFP intensities to their corresponding mean DAPI
425 intensities. A linear regression was performed to obtain the linear parameters f , o that map the
426 GFP channel image to the DAPI channel image. Cleaned DAPI images with a reduced *Brucella*
427 signal were obtained by subtracting the linear transform of the GFP channel from the DAPI
428 channel $I'_{\text{DAPI}} = I_{\text{DAPI}} - (f I_{\text{GFP}} + o)$ as pre-processing steps for every image prior to analysis.

429 On a random subset of 128 images, CellProfiler (61) was executed to identify Nucleus objects
430 using “OTSU Global” segmentation in the DAPI channel, and the median, lower quartile and
431 upper quartile segmentation thresholds of the images were retained as $T_{\text{DAPI-m}}$, $T_{\text{DAPI-lq}}$ and
432 $T_{\text{DAPI-uq}}$. On the same images, the GFP background intensity B_{GFP} was obtained as the position
433 of the peak in the GFP intensity histogram, the dynamic range of the histogram D_{GFP} was
434 obtained as the difference between the 99% quantile and the 1% quantile of intensity values,
435 and the Bacteria segmentation threshold was computed as $T_{\text{GFP}} = B_{\text{GFP}} + \frac{2}{100} D_{\text{GFP}}$. On all images,

436 screeningBee CellProfiler was executed to perform object segmentation and measurements
437 with the following steps: (a) Nuclei were detected as primary objects using manual threshold
438 setting. For each plate it was manually chosen to use $T_{\text{DAPI-m}}$, $T_{\text{DAPI-lq}}$ or $T_{\text{DAPI-ug}}$, depending on
439 visual inspection of the segmentation results. Using the same threshold on all images improved
440 site-to-site comparability. (b) Cells were detected as secondary objects around the Nuclei, with
441 “OTSU Global” segmentation in the RFP channel. (c) Bacteria were detected as primary
442 objects using manual threshold setting with threshold T_{GFP} . Using the fixed background
443 intensity as a reference for T_{GFP} allowed for segmenting even rather dim objects while avoiding
444 site-to-site variability. In order to accurately measure infection scoring, a reliable method to
445 associate pathogen colonies to individual cells is necessary. A straightforward approach is to
446 assume that pathogen colonies must be contained within the body of the host cell. However,
447 high cell confluence can make actin channel-based cell body segmentation inaccurate. Single
448 microcolonies are often split into pieces that are incorrectly assigned to neighboring cells using
449 this approach (Fig. 1B). To address this issue, we developed a novel algorithm to intelligently
450 assign pathogen colonies to robust nucleus objects (Fig. 1C). First, inexpensive ‘bridge’ and
451 ‘majority’ morphological operations were applied to the pathogen objects to connect broken
452 clumps. Next, a weighted distance metric was used to measure an attraction score $a_{N,P}$ between
453 a pathogen P and individual nuclei N within a close proximity d_{prox} . The attraction score is
454 computed as the surface integral of the nucleus area in a continuous field emanating from the
455 pathogen defined by an exponential function that is strongest within the microcolony itself, and
456 decays exponentially as distance from the microcolony increases: $a_{N,P} =$
457 $\sum_{n \in N} e^{-\lambda d_{n,p}}$, where n is an element (pixel) belonging to nucleus object N , $d_{n,p}$ is the
458 distance transform from the edge of microcolony P to n , and λ is a parameter controlling the
459 strength of the decay. Attraction scores for all nuclei proximate to microcolony P are
460 normalized such that the strongest nucleus attraction score is 1, $\underline{a}_{N,P} =$

461 $\frac{a_{N,P}}{\max(a_{N,P})} \forall N \quad s.t. d_{n,p} < d_{prox}$. Nuclei objects with normalized attraction scores above a
462 threshold a_{min} are associated with the pathogen microcolony. In the case that multiple nuclei
463 are associated with the same microcolony, the microcolony is split so that each element is
464 associated to the nearest nuclei. Large microcolonies are encouraged to split with greater ease
465 than small microcolonies by weakening the minimum attraction score linearly according to
466 area of the microcolony $a'_{min} = 0.5 a_{min}$ if $A_P < A_{large}$, or $a'_{min} = 1 - 0.5 \frac{A_P - A_{large}}{A_{large}} a_{min}$
467 if $A_{large} \leq A_P \leq 2A_{large}$, and $a'_{min} = 0.5 a_{min}$ otherwise (where A_P is the area of the
468 pathogen microcolony). Parameters settings $d_{prox} = 45$, $\lambda = 0.2$, $a_{min} = 0.5$, and
469 $A_{large} = 8,000$ were optimized by grid search on a dataset of 7,566 hand-labeled segmentations
470 resulting in a 95.58% correct association rate.

471 Nucleus to pathogen microcolonies associations were aggregated. The area and integrated
472 intensity of the pathogen objects associated to each cell and the mean intensity of the Nuclei in
473 the GFP channel was computed as readout.

474 **Infection scoring for endpoint assays**

475 Wells that contain only 32 Cells or less were excluded from infection scoring. In the remaining
476 wells, Bacteria were filtered in a decision tree (DT) classification to exclude objects of only
477 one-pixel area. Based on the relation of Bacteria to Nuclei, for the remaining Bacteria objects,
478 the integrated GFP intensity was integrated over all Bacteria relating to a Cell. To reduce the
479 impact of background intensity, an estimate for GFP background was computed using the 1%
480 lower quantile of mean GFP intensity in the Nuclei. For every Cell, the estimated GFP
481 background intensity was multiplied with the area of Bacteria relating to this cell, and the result
482 was subtracted from the integrated Bacteria GFP intensity of the Cell, to arrive at a background-
483 free estimate of “bacterial load” in each Cell. The value range for this intensity was zero for
484 Cells with no segmented Bacteria objects, and higher than zero for all other Cells. This

485 integrated GFP intensity was then log₂-scaled, to reflect the exponential growth of replicating
486 *Brucella*. Before log₂-scaling, a small epsilon value of 2⁻²⁰ was added to every Cell, so that the
487 log₂ value of Cells with no segmented Bacteria will not be negative infinity. The arbitrary
488 value 2⁻²⁰ is by a large margin smaller than the smallest actual intensity of our assays, but large
489 enough to be used in histogram binning. For every plate, the histogram of the log₂-scaled
490 integrated cellular GFP intensity was computed (Fig. 1D) with a bin size of 0.025. The
491 histograms were normalized to an arbitrary “virtual plate cell count” of 10¹⁰. To extrapolate a
492 continuous distribution from the possibly sparse histogram, kernel density estimation (KDE)
493 was used with a manually optimized Gaussian kernel of standard deviation 16. The histogram
494 shows a bimodal distribution. By correlating the plate histogram distributions to selected
495 images from the plate, we could identify that the first mode of the distribution is composed of
496 cells with a low number of infection events ranging from single *Brucella* to small clusters
497 (denoted as), whereas the second mode is composed of large colonies (denoted as). The two
498 peak positions of the bimodal distribution were identified. Normal distributions G_S and G_L were
499 fitted to the peak positions for small and large colonies, respectively. For the fitting of G_S and
500 G_L, the mean was given by the position of the peak, the height was given by the height of the
501 peak, and the variance was optimized such that the distance between the KDE and the sum of
502 G_S and G_L became minimal. To arrive at a binary infection scoring threshold, we identified a
503 suitable value three standard deviations below the mean of G_L. This threshold includes 99.8%
504 of the events in G_L. Cells with an integrated GFP intensity exceeding this threshold were
505 considered true positive infections and were labelled infected. The infection score was
506 computed as the ratio of infected Cells to the total number of Cells in the well.

507 **Redundant siRNA Analysis (RSA) and hit selection**

508 Redundant siRNA Analysis RSA (25) ranks genes by iteratively assigning hypergeometric p-
509 values to each of the multiple siRNAs targeting the same gene and picking the minimum value

510 within a given group to represent this gene. The ranking score indicates whether the distribution
511 of ranks corresponding to a gene is shifted towards the top, thereby aggregating the information
512 provided by independent siRNA sequences with the same target in a robust manner. Individual
513 siRNAs from the Qiagen library and the averages of independent replicates of the Dharmacon,
514 Ambion, and Sigma libraries (repeated experiments with identical siRNA) were used as input.
515 Prior to RSA analysis, siRNA targets were re-identified by searching against ENSEMBL
516 cDNA and the REFSEQ mRNA nucleotide data, in order to ensure comparability between
517 libraries. Cases where matching failed were excluded from this analysis. Data was further
518 filtered removing all wells that do not pass quality control, control wells and wells where cell
519 count was below the initially seeded cell number (500). As both up- and down hits are of
520 interest to this analysis, RSA was run twice, once with Z-scored infection scores ranked from
521 low to high values and once ranked oppositely. The RSA parameters were set as follows: upper
522 and lower bound (-0.5; -2) or (-0.5;-10) on averaged z-scored infection score for down and up-
523 hits, respectively. Bonferroni correction was applied to account for the different number of
524 siRNAs per gene. Genes matching a Benjamini-corrected RSA P-value ≤ 0.01 with more than
525 3 hit wells were considered as significant and selected for further analysis.

526 **Infection scoring for entry assays**

527 Wells containing only 32 Cells or less were excluded from infection scoring. In the remaining
528 wells, Bacteria were filtered in a decision tree (DT) classification to exclude objects of only
529 one pixel area. The remaining Bacteria were filtered in a DT classification to exclude objects
530 of less than a manually set threshold on the upper quartile of the object intensity. The remaining
531 Bacteria were considered true positive infections. Based on the relation of Bacteria to Nuclei,
532 Cells were labeled infected if and only if a true positive Bacteria is related to the Cells Nuclei.
533 The infection score was computed as the ratio of infected Cells to the total number of Cells in
534 the well. For quantification of bacterial load in infected cells, the median of integrated GFP

535 intensity of all true positive Bacteria was computed. The final infection readout was the product
536 of the infection rate and bacterial load, which gives a robust approximation of the amount of
537 intracellular bacteria (29).

538 **Rescue experiment**

539 The shRNA suppression/rescue constructs for VPS35 were kind gifts from Daniel Billadeau
540 (41). HeLa cells were seeded in a 6-well plate and transfected 4 h later with 0.9 µg of plasmid
541 DNA using Fugene HD according to the manufacturer's protocol. 72 h post-transfection cells
542 were reseeded into a 96-well plate (2'800 cells / well) and infected on the following day. Cells
543 were infected with *Brucella abortus* carrying pAC037 for 48 h. After PFA fixation and
544 staining, cells were analyzed by image analysis. Infection scoring was performed on YFP
545 positive cells, indicative of successful transfection.

546 **Determination of intracellular bacterial load by CFU determination**

547 Infections of siRNA-transfected Hela cells were performed in 96-well plates as described
548 above. At 6, 20, or 44 hpi, infected cells were washed with 200 µl PBS and lysed for 10 min
549 with 0.1 % Triton X-100 / PBS. Lysed cells (6 wells per conditions) were collected in 2 ml
550 screw-cap tubes and washed once with 1 ml PBS. Pellet was Resuspended in 1 ml PBS and
551 subjected to 5-fold serial dilution before plating onto TSA plate. CFU were counted after 3
552 days growth at 37°C and normalized to the CFU obtained by the scrambled siRNA-treated cells
553 from the matching biological replicate.

554 **Immunoblotting**

555 Proteins from total cell lysates (10 - 20 µg) were separated by SDS-PAGE, transferred onto
556 PVDF membranes (Hybond 0.2 µm, Amersham GE Life Sciences) and probed using the
557 indicated antibodies. The secondary HRP-conjugated antibody was visualized by
558 chemiluminescence (SeraCare developer Solution). For anti-tubulin probing, membranes were
559 first treated with stripping buffer (Thermo Scientific), washed and reprobred. Polyclonal rabbit

560 antibodies against VPS35 (ab97545, abcam), VPS29 (ab98929, abcam), rabbit monoclonal
561 antibody against VPS26 (ab98929, abcam) or mouse monoclonal antibody against β -tubulin
562 (T8328, Sigma) were used according to manufacturer's instructions. Quantification of
563 immunoblots was performed using ImageJ.

564 **Immunofluorescence for LAMP-1 co-localization**

565 Following fixation with 3.7% PFA in PBS for 20 min, HeLa cells were incubated in PBS
566 containing 250 mM glycine for 20 min to quench remaining aldehyde residues. Cells were then
567 permeabilized with saponin buffer (PBS containing 0.2% saponin and 3% bovine serum
568 albumin) for 1 h. Immunostaining was performed by incubating coverslips with saponin buffer
569 containing antibodies against LAMP-1 (Abcam ab25630) and *Brucella abortus* LPS polyclonal
570 rabbit serum (kind gift from Xavier De Bolle (62)) overnight in a humidified chamber at 4°C.
571 The coverslips were then washed three times with PBS and incubated with saponin buffer
572 containing respective fluorophore-conjugated secondary antibodies: goat anti-mouse Alexa
573 Fluor 488 (Thermo Fisher A11029) and anti-rabbit Alexa Fluor 647 (Cell Signaling #4414) for
574 3 h in a humidified chamber at room temperature. The coverslips were then washed three times
575 with PBS and mounted onto glass slides using Vectashield H-100 Antifade Mounting Medium
576 (Vector Laboratories) and sealed with nail polish.

577 **Confocal microscopy for single cell data**

578 The images were captured with the LSM-800 Confocal Microscope (Carl Zeiss) using a 63x
579 oil objective. For each condition, 40 images were obtained at random locations across the
580 coverslip, representing more than 50 individual cells per conditions. The images were
581 deconvolved using Huygens software (Scientific Volume Imaging). The presence of LAMP-1
582 signal around the bacteria was quantified from the images by assessing the overlap between
583 the anti-LPS and the anti-LAMP-1 staining for each individual bacterium (more than 400 per
584 condition).

585

586 **Acknowledgments**

587 We want to thank Julia Feldmann and Dr. Sonia Borrell from the SwissTPH, Basel, Switzerland
588 for great assistance and support with the BSL-3 environment. We are thankful to the Imaging
589 Core Facility of the Biozentrum, Basel for excellent assistance and advice with confocal
590 microscopy. We also thank Dr. Daniel Billadeau for sharing the VPS35 shRNA
591 suppression/rescue constructs. Finally, we thank Dr. Simone Eicher for help with the RSA
592 analysis and critical discussions. The genome sequence used in this research was derived from
593 a HeLa cell line. Henrietta Lacks, and the HeLa cell line that was established from her tumor
594 cells without her knowledge or consent in 1951, have made significant contributions to
595 scientific progress and advances in human health. We are grateful to Henrietta Lacks, now
596 deceased, and to her surviving family members for their contributions to biomedical
597 research. This study was reviewed by the NIH HeLa Genome Data Access Working Group
598 (<http://acd.od.nih.gov/hlgda.htm>). The genomic datasets used for analysis described in this
599 manuscript were obtained from the database of Genotypes and Phenotypes (dbGaP) through
600 dbGaP accession number phs000640.v1.p1. This work was supported by grants
601 31003A_173119 to CD from the Swiss National Science Foundation (SNSF, www.snf.ch),
602 advanced grant 340330 to CD (FicModFun) from the European Research Council (ERC), grant
603 51RTP0_151029 to CD for the Research and Technology Development (RTD) project
604 TargetInfectX in the frame of SystemsX.ch (www.systemX.ch), the Swiss Initiative for System
605 Biology. AC and SH were fellows of the ‘Fellowship of Excellence’ International PhD program
606 of the Biozentrum, University of Basel, Switzerland. HB benefited from the SNSF Flexibility
607 Grant.
608 AC and SL performed all genome-wide siRNA screening, AC performed the entry assays, ME,
609 KS, and AC designed and performed the image analysis for the screening and entry assays.

610 MQ, AC, and HB performed the analysis of the genome-wide datasets. MQ and AC analyzed
611 the entry assay datasets. TT, SL, and HB designed and performed the VPS35 rescue
612 experiment. TT and JS designed and performed the single cell experiment. TT, MQ, and MK.
613 performed the CFU and WB experiments. MQ and JS analyzed the single cell data. MQ, AC
614 and CD wrote the manuscript. CD provided strategic leadership for the project, designed
615 experiments, and discussed data. The authors declare no competing interests.

616

617 **References**

- 618 1. Creasey EA, Isberg RR. 2014. Maintenance of vacuole integrity by bacterial pathogens.
619 *Curr Opin Microbiol* 17:46-52.
- 620 2. Di Russo Case E, Samuel JE. 2016. Contrasting lifestyles within the host cell. *Microbiol*
621 *Spectr* 4.
- 622 3. Weber MM, Faris R. 2018. Subversion of the endocytic and secretory pathways by
623 bacterial effector proteins. *Front Cell Dev Biol* 6:1.
- 624 4. Havelaar AH, Kirk MD, Torgerson PR, Gibb HJ, Hald T, Lake RJ, Praet N, Bellinger
625 DC, de Silva NR, Gargouri N, Speybroeck N, Cawthorne A, Mathers C, Stein C,
626 Angulo FJ, Devleeschauwer B, World Health Organization Foodborne Disease
627 Burden Epidemiology Reference G. 2015. World Health Organization global estimates
628 and regional comparisons of the burden of foodborne disease in 2010. *PLoS Med*
629 12:e1001923.
- 630 5. Moreno E. 2014. Retrospective and prospective perspectives on zoonotic brucellosis.
631 *Front Microbiol* 5:213.
- 632 6. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV. 2006. The new global
633 map of human brucellosis. *Lancet Infect Dis* 6:91-9.

- 634 7. Ariza J, Bosilkovski M, Cascio A, Colmenero JD, Corbel MJ, Falagas ME, Memish
635 ZA, Roushan MR, Rubinstein E, Sipsas NV, Solera J, Young EJ, Pappas G,
636 International Society of C, Institute of Continuing Medical Education of I. 2007.
637 Perspectives for the treatment of brucellosis in the 21st century: the Ioannina
638 recommendations. PLoS Med 4:e317.
- 639 8. Sedzicki J, Tschon T, Low SH, Willemart K, Goldie KN, Letesson JJ, Stahlberg H,
640 Dehio C. 2018. 3D correlative electron microscopy reveals continuity of *Brucella*-
641 containing vacuoles with the endoplasmic reticulum. J Cell Sci 131.
- 642 9. Pizarro-Cerda J, Meresse S, Parton RG, van der Goot G, Sola-Landa A, Lopez-Goni I,
643 Moreno E, Gorvel JP. 1998. *Brucella abortus* transits through the autophagic pathway
644 and replicates in the endoplasmic reticulum of nonprofessional phagocytes. Infect
645 Immun 66:5711-24.
- 646 10. Starr T, Ng TW, Wehrly TD, Knodler LA, Celli J. 2008. *Brucella* intracellular
647 replication requires trafficking through the late endosomal/lysosomal compartment.
648 Traffic 9:678-94.
- 649 11. Castaneda-Roldan EI, Avelino-Flores F, Dall'Agnol M, Freer E, Cedillo L, Dornand J,
650 Giron JA. 2004. Adherence of *Brucella* to human epithelial cells and macrophages is
651 mediated by sialic acid residues. Cell Microbiol 6:435-45.
- 652 12. Castaneda-Roldan EI, Ouahrani-Bettache S, Saldana Z, Avelino F, Rendon MA,
653 Dornand J, Giron JA. 2006. Characterization of SP41, a surface protein of *Brucella*
654 associated with adherence and invasion of host epithelial cells. Cell Microbiol 8:1877-
655 87.
- 656 13. Guzman-Verri C, Chaves-Olarte E, von Eichel-Streiber C, Lopez-Goni I, Thelestam M,
657 Arvidson S, Gorvel JP, Moreno E. 2001. GTPases of the Rho subfamily are required

- 658 for *Brucella abortus* internalization in nonprofessional phagocytes: direct activation of
659 Cdc42. J Biol Chem 276:44435-43.
- 660 14. Arellano-Reynoso B, Lapaque N, Salcedo S, Briones G, Ciocchini AE, Ugalde R,
661 Moreno E, Moriyon I, Gorvel JP. 2005. Cyclic beta-1,2-glucan is a *Brucella* virulence
662 factor required for intracellular survival. Nat Immunol 6:618-25.
- 663 15. Bellaire BH, Roop RM, 2nd, Cardelli JA. 2005. Opsonized virulent *Brucella abortus*
664 replicates within nonacidic, endoplasmic reticulum-negative, LAMP-1-positive
665 phagosomes in human monocytes. Infect Immun 73:3702-13.
- 666 16. Celli J, de Chastellier C, Franchini DM, Pizarro-Cerda J, Moreno E, Gorvel JP. 2003.
667 *Brucella* evades macrophage killing via VirB-dependent sustained interactions with the
668 endoplasmic reticulum. J Exp Med 198:545-56.
- 669 17. Boschirolu ML, Ouahrani-Bettache S, Foulongne V, Michaux-Charachon S, Bourg G,
670 Allardet-Servent A, Cazevieille C, Liautard JP, Ramuz M, O'Callaghan D. 2002. The
671 *Brucella suis virB* operon is induced intracellularly in macrophages. Proc Natl Acad
672 Sci U S A 99:1544-9.
- 673 18. Comerci DJ, Martinez-Lorenzo MJ, Sieira R, Gorvel JP, Ugalde RA. 2001. Essential
674 role of the VirB machinery in the maturation of the *Brucella abortus*-containing
675 vacuole. Cell Microbiol 3:159-68.
- 676 19. Ke Y, Wang Y, Li W, Chen Z. 2015. Type IV secretion system of *Brucella* spp. and its
677 effectors. Front Cell Infect Microbiol 5:72.
- 678 20. Miller CN, Smith EP, Cundiff JA, Knodler LA, Bailey Blackburn J, Lupashin V, Celli
679 J. 2017. A *Brucella* type IV effector targets the COG tethering complex to remodel host
680 secretory traffic and promote intracellular replication. Cell Host Microbe 22:317-329
681 e7.

- 682 21. Franceschini A, Meier R, Casanova A, Kreibich S, Daga N, Andritschke D, Dilling S,
683 Ramo P, Emmenlauer M, Kaufmann A, Conde-Alvarez R, Low SH, Pelkmans L,
684 Helenius A, Hardt WD, Dehio C, von Mering C. 2014. Specific inhibition of diverse
685 pathogens in human cells by synthetic microRNA-like oligonucleotides inferred from
686 RNAi screens. *Proc Natl Acad Sci U S A* 111:4548-53.
- 687 22. Ramo P, Drewek A, Arrieumerlou C, Beerenwinkel N, Ben-Tekaya H, Cardel B,
688 Casanova A, Conde-Alvarez R, Cossart P, Csucs G, Eicher S, Emmenlauer M, Greber
689 U, Hardt WD, Helenius A, Kasper C, Kaufmann A, Kreibich S, Kuhbacher A, Kunszt
690 P, Low SH, Mercer J, Mudrak D, Muntwiler S, Pelkmans L, Pizarro-Cerda J, Podvinec
691 M, Pujadas E, Rinn B, Rouilly V, Schmich F, Siebourg-Polster J, Snijder B, Stebler M,
692 Studer G, Szczurek E, Truttmann M, von Mering C, Vonderheit A, Yakimovich A,
693 Buhlmann P, Dehio C. 2014. Simultaneous analysis of large-scale RNAi screens for
694 pathogen entry. *BMC Genomics* 15:1162.
- 695 23. Québatte M, Dehio C. 2017. Systems-level interference strategies to decipher host
696 factors involved in bacterial pathogen interaction: from RNAi to CRISPRi. *Curr Opin*
697 *Microbiol* 39:34-41.
- 698 24. Zhu J, Davoli T, Perriera JM, Chin CR, Gaiha GD, John SP, Sigiollot FD, Gao G, Xu
699 Q, Qu H, Pertel T, Sims JS, Smith JA, Baker RE, Maranda L, Ng A, Elledge SJ, Brass
700 AL. 2014. Comprehensive identification of host modulators of HIV-1 replication using
701 multiple orthologous RNAi reagents. *Cell Rep* 9:752-66.
- 702 25. Konig R, Chiang CY, Tu BP, Yan SF, DeJesus PD, Romero A, Bergauer T, Orth A,
703 Krueger U, Zhou Y, Chanda SK. 2007. A probability-based approach for the analysis
704 of large-scale RNAi screens. *Nat Methods* 4:847-9.
- 705 26. Huang da W, Sherman BT, Lempicki RA. 2009. Systematic and integrative analysis of
706 large gene lists using DAVID bioinformatics resources. *Nat Protoc* 4:44-57.

- 707 27. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A,
708 Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. 2017. The STRING database
709 in 2017: quality-controlled protein-protein association networks, made broadly
710 accessible. *Nucleic Acids Res* 45:D362-D368.
- 711 28. Keriél A, Botella E, Estrach S, Bragagnolo G, Vergunst AC, Feral CC, O'Callaghan D.
712 2015. *Brucella* intracellular life relies on the transmembrane protein CD98 heavy chain.
713 *J Infect Dis* 211:1769-78.
- 714 29. Casanova A, Low SH, Emmenlauer M, Conde-Alvarez R, Salcedo SP, Gorvel JP,
715 Dehio C. 2016. Microscopy-based assays for high-throughput screening of host factors
716 involved in *Brucella* infection of HeLa cells. *J Vis Exp*
717 doi:<https://www.doi.org/10.3791/54263>.
- 718 30. Morth JP, Pedersen BP, Buch-Pedersen MJ, Andersen JP, Vilsen B, Palmgren MG,
719 Nissen P. 2011. A structural overview of the plasma membrane Na⁺,K⁺-ATPase and
720 H⁺-ATPase ion pumps. *Nat Rev Mol Cell Biol* 12:60-70.
- 721 31. Siezen RJ, Leunissen JA. 1997. Subtilases: the superfamily of subtilisin-like serine
722 proteases. *Protein Sci* 6:501-23.
- 723 32. Gallon M, Cullen PJ. 2015. Retromer and sorting nexins in endosomal sorting. *Biochem*
724 *Soc Trans* 43:33-47.
- 725 33. Wang J, Fedoseienko A, Chen B, Burstein E, Jia D, Billadeau DD. 2018. Endosomal
726 receptor trafficking: Retromer and beyond. *Traffic* 19:578-590.
- 727 34. Linxweiler M, Schick B, Zimmermann R. 2017. Let's talk about Secs: Sec61, Sec62
728 and Sec63 in signal transduction, oncology and personalized medicine. *Signal*
729 *Transduct Target Ther* 2:17002.

- 730 35. Qin QM, Pei J, Ancona V, Shaw BD, Ficht TA, de Figueiredo P. 2008. RNAi screen of
731 endoplasmic reticulum-associated host factors reveals a role for IRE1alpha in
732 supporting *Brucella* replication. PLoS Pathog 4:e1000110.
- 733 36. Steinberg F, Gallon M, Winfield M, Thomas EC, Bell AJ, Heesom KJ, Tavare JM,
734 Cullen PJ. 2013. A global analysis of SNX27-retromer assembly and cargo specificity
735 reveals a function in glucose and metal ion transport. Nat Cell Biol 15:461-71.
- 736 37. Temkin P, Lauffer B, Jager S, Cimermancic P, Krogan NJ, von Zastrow M. 2011.
737 SNX27 mediates retromer tubule entry and endosome-to-plasma membrane trafficking
738 of signalling receptors. Nat Cell Biol 13:715-21.
- 739 38. Seaman MN, McCaffery JM, Emr SD. 1998. A membrane coat complex essential for
740 endosome-to-Golgi retrograde transport in yeast. J Cell Biol 142:665-81.
- 741 39. Kvainickas A, Jimenez-Orgaz A, Nagele H, Hu Z, Dengjel J, Steinberg F. 2017. Cargo-
742 selective SNX-BAR proteins mediate retromer trimer independent retrograde transport.
743 J Cell Biol 216:3677-3693.
- 744 40. Simonetti B, Danson CM, Heesom KJ, Cullen PJ. 2017. Sequence-dependent cargo
745 recognition by SNX-BARs mediates retromer-independent transport of CI-MPR. J Cell
746 Biol 216:3695-3712.
- 747 41. Liu TT, Gomez TS, Sackey BK, Billadeau DD, Burd CG. 2012. Rab GTPase regulation
748 of retromer-mediated cargo export during endosome maturation. Mol Biol Cell
749 23:2505-15.
- 750 42. Elwell C, Engel J. 2018. Emerging role of retromer in modulating pathogen growth.
751 Trends Microbiol 26:769-780.
- 752 43. Personnic N, Barlocher K, Finsel I, Hilbi H. 2016. Subversion of retrograde trafficking
753 by translocated pathogen effectors. Trends Microbiol 24:450-462.


- 754 44. Elwell CA, Czudnochowski N, von Dollen J, Johnson JR, Nakagawa R, Mirrashidi K,
755 Krogan NJ, Engel JN, Rosenberg OS. 2017. *Chlamydia* interfere with an interaction
756 between the mannose-6-phosphate receptor and sorting nexins to counteract host
757 restriction. *Elife* 6.
- 758 45. Mirrashidi KM, Elwell CA, Verschueren E, Johnson JR, Frando A, Von Dollen J,
759 Rosenberg O, Gulbahce N, Jang G, Johnson T, Jager S, Gopalakrishnan AM, Sherry J,
760 Dunn JD, Olive A, Penn B, Shales M, Cox JS, Starnbach MN, Derre I, Valdivia R,
761 Krogan NJ, Engel J. 2015. Global mapping of the Inc-human interactome reveals that
762 retromer restricts chlamydia infection. *Cell Host Microbe* 18:109-21.
- 763 46. Yin P, Hong Z, Yang X, Chung RT, Zhang L. 2016. A role for retromer in hepatitis C
764 virus replication. *Cell Mol Life Sci* 73:869-81.
- 765 47. Yao J, Yang F, Sun X, Wang S, Gan N, Liu Q, Liu D, Zhang X, Niu D, Wei Y, Ma C,
766 Luo ZQ, Sun Q, Jia D. 2018. Mechanism of inhibition of retromer transport by the
767 bacterial effector RidL. *Proc Natl Acad Sci U S A* 115:E1446-E1454.
- 768 48. Romano-Moreno M, Rojas AL, Williamson CD, Gershlick DC, Lucas M, Isupov MN,
769 Bonifacino JS, Machner MP, Hierro A. 2017. Molecular mechanism for the subversion
770 of the retromer coat by the *Legionella* effector RidL. *Proc Natl Acad Sci U S A*
771 114:E11151-E11160.
- 772 49. Barlocher K, Hutter CAJ, Swart AL, Steiner B, Welin A, Hohl M, Letourneur F, Seeger
773 MA, Hilbi H. 2017. Structural insights into *Legionella* RidL-Vps29 retromer subunit
774 interaction reveal displacement of the regulator TBC1D5. *Nat Commun* 8:1543.
- 775 50. Patrick KL, Wojcechowskyj JA, Bell SL, Riba MN, Jing T, Talmage S, Xu P, Cabello
776 AL, Xu J, Shales M, Jimenez-Morales D, Ficht TA, de Figueiredo P, Samuel JE, Li P,
777 Krogan NJ, Watson RO. 2018. Quantitative yeast genetic interaction profiling of

- 778 bacterial effector proteins uncovers a role for the human retromer in *Salmonella*
779 infection. *Cell Syst* 7:323-338 e6.
- 780 51. Harbour ME, Breusegem SY, Antrobus R, Freeman C, Reid E, Seaman MN. 2010. The
781 cargo-selective retromer complex is a recruiting hub for protein complexes that regulate
782 endosomal tubule dynamics. *J Cell Sci* 123:3703-17.
- 783 52. Harrison MS, Hung CS, Liu TT, Christiano R, Walther TC, Burd CG. 2014. A
784 mechanism for retromer endosomal coat complex assembly with cargo. *Proc Natl Acad*
785 *Sci U S A* 111:267-72.
- 786 53. Seaman MN, Harbour ME, Tattersall D, Read E, Bright N. 2009. Membrane
787 recruitment of the cargo-selective retromer subcomplex is catalysed by the small
788 GTPase Rab7 and inhibited by the Rab-GAP TBC1D5. *J Cell Sci* 122:2371-82.
- 789 54. Jimenez-Orgaz A, Kvainickas A, Nagele H, Denner J, Eimer S, Dengjel J, Steinberg F.
790 2018. Control of RAB7 activity and localization through the retromer-TBC1D5
791 complex enables RAB7-dependent mitophagy. *EMBO J* 37:235-254.
- 792 55. Lee JJ, Kim DG, Kim DH, Simborio HL, Min W, Lee HJ, Her M, Jung SC, Watarai M,
793 Kim S. 2013. Interplay between clathrin and Rab5 controls the early phagocytic
794 trafficking and intracellular survival of *Brucella abortus* within HeLa cells. *J Biol*
795 *Chem* 288:28049-57.
- 796 56. Elfaki MG, Al-Hokail AA. 2009. Transforming growth factor beta production
797 correlates with depressed lymphocytes function in humans with chronic brucellosis.
798 *Microbes Infect* 11:1089-96.
- 799 57. Goenka R, Parent MA, Elzer PH, Baldwin CL. 2011. B cell-deficient mice display
800 markedly enhanced resistance to the intracellular bacterium *Brucella abortus*. *J Infect*
801 *Dis* 203:1136-46.

- 802 58. Celli J, Salcedo SP, Gorvel JP. 2005. *Brucella* coopts the small GTPase Sar1 for
803 intracellular replication. Proc Natl Acad Sci U S A 102:1673-8.
- 804 59. Thanbichler M, Iniesta AA, Shapiro L. 2007. A comprehensive set of plasmids for
805 vanillate- and xylose-inducible gene expression in *Caulobacter crescentus*. Nucleic
806 Acids Res 35:e137.
- 807 60. Smith K, Li Y, Piccinini F, Csucs G, Balazs C, Bevilacqua A, Horvath P. 2015. CIDRE:
808 an illumination-correction method for optical microscopy. Nat Methods 12:404-6.
- 809 61. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, Guertin DA,
810 Chang JH, Lindquist RA, Moffat J, Golland P, Sabatini DM. 2006. CellProfiler: image
811 analysis software for identifying and quantifying cell phenotypes. Genome Biol
812 7:R100.
- 813 62. Deghelt M, Mullier C, Sternon JF, Francis N, Laloux G, Dotreppe D, Van der Henst C,
814 Jacobs-Wagner C, Letesson JJ, De Bolle X. 2014. G1-arrested newborn cells are the
815 predominant infectious form of the pathogen *Brucella abortus*. Nat Commun 5:4366.
- 816 63. Keleher LL, Skyberg JA. 2016. Activation of bovine neutrophils by *Brucella* spp. Vet
817 Immunol Immunopathol 177:1-6.
- 818 64. Starr T, Child R, Wehrly TD, Hansen B, Hwang S, Lopez-Otin C, Virgin HW, Celli J.
819 2012. Selective subversion of autophagy complexes facilitates completion of the
820 *Brucella* intracellular cycle. Cell Host Microbe 11:33-45.
- 821

822 **Figure legend (figure included for review)**

823 **Figure 1**



824

825 **Fig. 1 Overview of the high-content screening and analysis.** (A) Summary of RNAi

826 screening workflow. Reverse transfection of HeLa cells was performed in 384-well format for

827 72 h followed by 48 h infection with GFP expressing *B. abortus*, PFA fixation, and staining of

828 HeLa cells with DAPI and DY-547-Phalloidin before automated imaging. (B) Image analysis

829 was performed with CellProfiler to segment nuclei and bacteria and to extract measurements.

830 (C) Accurate association of segmented bacteria to nuclei enables quantitative single cell

831 measurements. The naive association (middle image) of segmented pathogen can be affected

832 by over-splitting in dense cell populations (left image). Our proposed solution (right image)

833 based on a nucleus attraction score. (D) The plate histogram shows the bimodal distribution of

834 integrated GFP intensity corresponding to *Brucella* replication. Intensity on the X-axis is \log_2 -


835 scaled to account for exponential growth. The normal distribution fitted (red curve) to the

836 Kernel Density Estimation of the histogram allows to compute a robust binary infection

837 threshold (dashed line) separating HeLa cells with (right) and without (left) replicating

838 *Brucella*. Associated are samples of single-cell images corresponding to the intervals of the
839 intensity distribution (for more details see Materials and Methods).


840 **Figure 2**



841

842 **Fig. 2 The human infectome for *Brucella* infection determined by genome-wide siRNA**
843 **screening.** (A) Representative merged images from the genome wide screen showing nuclei
844 (DAPI) and intracellular replication of GFP expressing *Brucella abortus* for either control
845 conditions (scramble) or a panel of identified hits (RAB7A, FGFR1, ACTR3, TGFBR2,
846 VPS35, ANLN and AP2S1). Scale bar = 100 μ m. (B, C, D) Results of gene ontology
847 enrichment analysis (DAVID) for the entire hit list (B), the down- (C) or up-hits (D). The
848 $[-\log_{10}]$ of the P-value associated to the different categories are indicated (cut-off: Benjamini
849 corrected P-value ≤ 0.01 , with more than 3 hit wells) as well as the number of individual
850 components associated to the displayed categories are indicated. In (B), the first number refers
851 to down-hits and the second to up-hits. (E, F) High confidence protein-protein interaction
852 networks ($x \geq 0.8$) for the 223 RSA down- (A) or 202 up-hits (B) determined using the STRING
853 database. Clusters with common predicted cellular function are colored and their prominent
854 function are indicated. Hits previously reported to be involved in *Brucella* pathogenicity are
855 highlighted: ARPC3 (29); TGFBR2 (22); SEC61G and TMED2 (35); RAC1 and CDC42 (13);
856 SLC3A2 (28); RAB7A (10); SYK (63); ULK1 (64); For clarity, disconnected components are
857 not displayed. The complete list of down- and up-hits is presented in Tables S1-S2. Data from
858 single RNAi reagents for down- and up-hits is presented in Fig S2-S3.
859

860 **Figure 3**



861

862 **Fig. 3 Entry assay identifies new components required for post-entry processes during**

863 ***Brucella* infection.** (A) Representative images from the entry assay showing nuclei (DAPI) of

864 HeLa cells and intracellular *Brucella abortus* (GFP) for control condition (mock) and cells

865 treated with siRNAs against CDC42 or VPS35. Scale bar = 100 μ m. HeLa cells were infected

866 with *B. abortus* expressing GFP under a tetracycline inducible system for 8 h (see Material and

867 Methods). (B) Scatter plot in double logarithmic scale showing infection scores measured for

868 the entry assay (8 hpi) versus endpoint assay (48 hpi), normalized to the respective mock

869 dataset (Table S3). For the entry assay, cells containing single bacteria were considered as

870 infected and the final readout is proportional to the median number of bacteria per infected


871 cells. For the endpoint assay, only cells containing replicating bacteria were considered as

872 infected (Fig. 1 and Materials and Methods). Each data point corresponds to the average of all

873 siRNAs or esiRNAs targeted against the gene of interest (n=3). The straight fit (oblique line,

874 $r^2 = 0.763$) indicates a globally high correlation between both assays. The blue box comprise
875 all points within ± 1 SD to the fitted data. The genes falling out of this range are marked in red.
876 For ease of visualization, only the averaged values over all RNAi products targeting a given
877 gene are displayed.

878 **Figure 4**



879

880 **Fig. 4 The VPS retromer is a key component of *Brucella* intracellular trafficking. (A)**


881 Schematic representation of the retromer components and their prominent interactors. (B)

882 Schematic representation of the shRNA constructs used in (C). The gray box on the shVPS35

883 /Rescue construct indicates the silent mutations that prevent recognition by to the co-expressed

884 shRNA (41). (C) Infection index from transfected cells. Displayed are the averaged infection
885 index and associated standard deviation after 48 h of *Brucella* infection. Data was normalized
886 to the YFP only condition (n=3). Asterisks indicate statistically significant difference to
887 scrambled YFP only condition as determined by paired t-test (* Pval \leq 0.01, ns not significant).
888 (D) Dot box representation of the z-scored infection score for components of the retromer and
889 interactors, including the positive control ARPC3. Asterisks indicate statistically significant
890 difference to scrambled siRNA-treated bacteria (Ctrl) as determined by one-way ANOVA and
891 Dunnett's multiple comparisons test (** Pval \leq 0.001; ns not significant). (E) Normalized
892 colony forming units (CFU) recovered from siRNA-treated cells a 6, 20 or 44 hpi. The
893 presented data correspond to CFU count normalized to control-siRNA-treated cells (n=3).
894 Significance was determined using One-way ANOVA with Dunnet's multiple comparison test
895 (* Pval \leq 0.01; ** \leq 0.001; ns not significant). (F) Western blot analysis of the indicated
896 proteins in total lysate of Hela cells treated with siRNA targeting the designated genes, 72 h
897 post transfection. Displayed is a representative example of an experiment performed in
898 biological triplicate (n=3). See Table S4 for the matching averaged intensity quantification.

899 **Figure 5**



900

901 **Fig. 5 VPS35 is required for *Brucella* to escape the lysosomal pathway. (A)**

902 Immunofluorescence approach used to quantify localization of *Brucella* within LAMP-1

903 positive vesicles, illustrated with a representative example of control-treated cells 6 hpi.

904 Individual channels and merged picture are presented. Arrows indicate examples of co-

905 colocalization of bacteria with LAMP-1 positive compartments. Staining of *Brucella* LPS (α LPS)

906 was used to confirm the presence of LAMP-1 in direct proximity of the bacterial surface.

907 Asterisks indicate examples of LAMP-1 negative *Brucella*. **(B)** Representative images from



908 *Brucella* infected cells either mock transfected (ctrl) or after VPS35 knockdown (siVPS35).

909 Samples were fixed 6 and 18 hpi. For clarity only the LAMP-1 (cyan) and dsRed (magenta)

910 channels are presented. Scale bar: 5 μ m. (C) Global quantification of LAMP-1 negative
911 *Brucella*. Displayed are the average and associated standard deviation for more than 500
912 bacteria and more than 50 HeLa cells per time point and condition (n=3). (D) Single-cell data
913 representation of the data presented in (C). Displayed is the distribution of LAMP-1 positive
914 *Brucella* per cell as a function of the total number of bacteria counted in that given cell.
915

916 Supporting information legends

917 Supporting Figure S1




918

919 **Fig. S1. Overview of the genome-wide dataset.** (A) Scatter plot representation of the z-scored
 920 averaged infection score plotted against the z-scored averaged cell count for all tested genes,
 921 with up- and down-hits highlighted in green and red respectively. (A). Linear regression
 922 between both parameters and associated r^2 value are indicated, suggesting no direct correlation

923 between infection score and cell count. **(B)** Box-blot representing averaged cell count score
924 (single gene level) for different hit categories. Albeit of rather modest amplitude, a highly
925 significant decrease in mean cell count is observed for both up- and down-hits. **(C)** Box-blot
926 representing averaged cell count score (averaged per siRNA) for the KIF11 control compared
927 to all targeting siRNAs or non-targeting controls. Cell number reduction in KIF11-transfected
928 cells reached 97.6% (91.5 – 99.99). Statistical test for (B, C): Unpaired t-test with Welch's
929 correction, P-value < 0.0001.
930

931 **Supporting Figure S2**



932

933 **Fig. S2 Data from single RNAi reagents for the selected 223 down-hits. (A-C) Averaged**


934 infection score (z-scored) and associated standard deviation for each of the 223 down-hits

935 (RSA analysis). Displayed are the results of each tested RNAi reagents (siRNA or esiRNA),

936 averaged by biological replicate. RNAi providers are differentiated by the shape used to

937 indicate the data point.

938 **Supporting Figure S3**



939

940 **Fig. S3 Data from single RNAi reagents for the selected 203 up-hits. (A-C) Averaged**
 941 **infection score (z-scored) and associated standard deviation for each of the 203 up-hits (RSA**
 942 **analysis). Displayed are the results of each tested RNAi reagents (siRNA or esiRNA), averaged**

943 by biological replicate. RNAi providers are differentiated by the shape used to indicate the data
944 point.

945 **Supporting Table S1 (SupportingTableS1-2.xls)**

946 List of the 223 down-hits from the genome-wide siRNA screen (RSA analysis) with associated
947 p-value and infection score (cut-off: RSA p-value <0.01, S1_Table.xlsx).

948 **Supporting Table S2 (SupportingTableS1-2.xls)**

949 List of the 202 up-hits from the genome-wide siRNA screen (RSA analysis) with associated p-
950 value and infection score (cut-off: RSA p-value <0.01, S2_Table.xlsx).

951 **Supporting Table S3 (SupportingTableS3.xls)**

952 Aggregated image analysis data used for Figure 3, with associated infection scores for both
953 entry and endpoint assays. Single data points and averaged data per siRNA and per genes (as
954 displayed in Fig. 3B) are indicated (S3_Table.xlsx).

955 **Supporting Table S4**

siRNA	VPS35		VPS29		VPS26	
	AVG	SD	AVG	SD	AVG	SD
siVPS35	21.5	± 2.4	25.8	± 11.5	25.1	± 6.2
siVPS29	105.8	± 10.4	6.6	± 5.3	90.2	± 36.8
siVPS26A	65.5	± 13.9	21.1	± 21.5	10.6	± 2.9
siVPS26A/B	49.5	± 12.9	23.7	± 31.3	5.5	± 3.3

956

957 Intensity quantification from Western blot analysis of siRNA-treated HeLa cells. Presented are
958 the averaged normalized intensities and associated standard deviation (n=3) for each VPS
959 retromer protein upon knockdown of the indicated gene. Normalized intensities correspond to
960 the intensity of the designated proteins divided by the intensity of the tubulin signal obtained
961 for the same sample, on the same blot.